Department of Diagnostic Imaging, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL, 33612, USA.
Department of Radiology, University of South Florida, 2 Tampa General Circle, STC 7028, Tampa, FL, 33606, USA.
Abdom Radiol (NY). 2019 Feb;44(2):766-774. doi: 10.1007/s00261-018-1752-4.
Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.
肿瘤影像学是腹部影像学的一个重要方面，放射科医生几乎每天都会遇到。许多肿瘤临床试验都使用实体瘤反应评估标准（RECIST）1.1 版，该标准将肿瘤部位分为靶病灶和非靶病灶。尽管 RECIST v1.1 为临床试验中使用影像学提供了明确的指导，但使用这些标准进行反应评估仍会出现错误。在非靶病灶的反应评估方面尤其如此，因为这些规则定义不太明确，有些主观。本文综述了 RECIST v1.1 指南和在基线和随访反应评估中可能出现的常见非靶病灶错误。
